Daniel A. Colón Ríos presents research at #AACR26 showing how IDH1-mutant cancers develop resistance to #PARP inhibitors. Work from the #GlazerLab identified key pathways behind PARPi resistance any d points to potential strategies to overcome it.
@theaacr.bsky.social @oncoalert.bsky.social
Dr. Zaira Ianniello #GlazerLab argues that V66-Exatecan is the best candidate for next generation ADC with a favorable safety profile, high potency in DDR deficient tumors, and efficacy that crosses the blood-brain barrier. #AACR25
@theaacr.bsky.social @yaleschoolofmed.bsky.social
